Human BioSystems
U.S. Patent Office Issues Human BioSystems Patent
Human BioSystems / Miscellaneous Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer / publisher is solely responsible for the content of this announcement. ---------------------------------------------------------------------- U.S. Patent Office Issues Human BioSystems Patent # 7,202,020 - 'Compositions, Methods and Apparatuses for Preserving Platelets' Palo Alto, CA – May 10, 2007 - (OTCBB:HBSC) - Human BioSystems (HBS), developer of preservation platforms for organs, blood platelets and other biomaterials, announced in a press release dated January 22, 2007 that the U.S. Patent Office will allow the Company’s fifth patent. The U.S. Patent Office has now issued patent number 7,202,020 to HBS for this patent entitled 'Compositions, Methods and Apparatuses for Preserving Platelets.' HBS has now received five U.S. patents related to organ, platelet and biological material preservation. HBS’ intellectual property portfolio consists of the following patents: 1. Methods and Apparatus for Preserving Biological Materials – U.S. Patent # 6,413,713 2. Methods and Apparatuses for Preserving Platelets – U.S. Patent # 6,828,090 3. Methods and Solutions for Storing Donor Organs – U.S. Patent # 7,029,839 4. Preservation of Blood Platelets with Citrate – U.S. Patent # 7,083,910 5. Compositions, Methods and Apparatuses for Preserving Platelets – U.S. Patent #7,202,020 Four of the five patents issued to HBS relate to the preservation of blood platelets, a blood component critical to cancer patients that have undergone chemotherapy/radiation treatments. Platelet infusions are necessary for a period of time following such cancer treatments to maintain adequate platelet counts. The lack of platelets could increase the chances of bleeding. David Winter, MD and President of Human BioSystems said, 'HBS intends to extend the preservation time of platelets beyond current standards while maintaining quality and safety by utilizing patented cooling methods not achieved by others thus far in the commercial blood banking industry. If successful, this could result in many of millions of dollars in savings to blood centers and hospitals worldwide.' HBS is headquartered in Palo Alto, California with research facilities in Michigan. Human BioSystems (OTC Bulletin Board: HBSC) Contact: Human BioSystems Investor Relations Harry Masuda Yes International CEO Rich Kaiser (650) 323-0943 (800) 631-8127 hmasuda@humanbiosystems.com rich@yesinternational.com Certain statements contained herein are 'forward-looking'' statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, results from ongoing research and development as well as clinical studies, failure to obtain regulatory approval for the Company’s products, if required, failure to develop a product based on the Company’s technology, failure of any such products to compete effectively with existing products, the inability to find a strategic partner or to consummate a relationship with a potential strategic partner on acceptable terms, the effectiveness of protection of the Company’s intellectual property, and other factors discussed in filings made by the Company with the Securities and Exchange Commission. DGAP 14.05.2007 ----------------------------------------------------------------------
Latest News
Latest Reports
Upcoming Events
No Events found